Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Drug: Ixabepilone; Drug: Bevacizumab
Sponsors: Yale University; R-Pharm-US, LLC
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 22, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments